查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611236

代谢紊乱治疗的市场规模、份额和趋势分析报告：按疾病、治疗方法、给药途径、分销管道、地区和细分市场进行预测，2025-2030年

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

代谢紊乱治疗市场的成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球代谢疾病治疗市场规模将达到1,207.1亿美元，2025年至2030年复合年增长率为7.8%。糖尿病、肥胖症和高胆固醇症的增加预计将推动市场成长。据估计，到 2040 年，全球大约每 11 人中就有 1 人将受到上述疾病之一的影响。

负责人预测，未来20年，肥胖和糖尿病等代谢性疾病的盛行率将翻倍，尤其是在美国以及亚洲和拉丁美洲国家。预计这将支持整个市场的未来成长。此外，随着新兴国家经济的稳定，对一次性治疗的新疗法的需求正在增加。因此，全球市场的领先公司正在大力投资研发，以开发创新治疗方法。所有这些因素都可能有助于市场发展。

代谢紊乱治疗市场报告亮点

  • 糖尿病在市场上占据主导地位，到 2024 年将占 29.8% 的份额。这是由于糖尿病，特别是第 2 型糖尿病的盛行率不断上升，影响了全球 5% 以上的人口。
  • 溶小体贮积症 (LSD) 预计在预测期内将以 9.3% 的最快复合年增长率成长。 LSD 是一种由酵素缺乏引起的进行性神经系统疾病，会导致严重症状和过早死亡。
  • 酵素替代疗法（ERT）在 2024 年以 30.6% 的销售份额引领市场。 ERT 针对与溶小体贮积症相关的基本酵素缺乏症，并显着改善患者的健康和生活品质。
  • 基因治疗预计在预测期内增长最快，达到 9.7%。基因疗法具有巨大的潜力，可以为治疗选择有限的遗传性代谢疾病提供治疗解决方案。
  • 由于起效快和生物利用度高，肠外治疗在 2024 年占据了最大的市场占有率，达到 50.0%。肠胃外给药可有效绕过胃肠道，以避免首过代谢并提供即时的治疗效果。
  • 预计口服治疗在预测期内的复合年增长率将达到 8.2%。口服给药是非侵入性的，更容易让患者自行给药，通常优于注射，可提高治疗顺从性
  • 医院药局占据市场主导地位，2024 年销售份额为 44.6%。医院药局在配发复杂药物方面发挥重要作用，尤其是那些需要专门处理的代谢性疾病药物。
  • 北美代谢紊乱治疗市场在2024年以39.9%的销售份额主导全球市场。北美拥有强大的医疗基础设施、大量的研发投资以及糖尿病和肥胖等代谢疾病的高发生率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章代谢性疾病治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章代谢紊乱治疗市场：疾病业务分析

  • 2024年及2030年疾病市场占有率
  • 疾病细分仪表板
  • 2018-2030 年按疾病分類的市场规模、预测与趋势分析
  • 溶小体贮积症
  • 糖尿病
  • 肥胖
  • 遗传性代谢疾病
  • 高胆固醇症
  • 其他代谢性疾病

第五章代谢紊乱治疗市场：治疗方法业务分析

  • 2024 年和 2030 年治疗方法市场占有率
  • 治疗方法细分仪表板
  • 2018-2030 年市场规模及预测与趋势分析（按治疗方法）
  • 酵素替代疗法
  • 细胞移植
  • 基于小分子的治疗方法
  • 基材减少疗法
  • 基因治疗
  • 药物治疗

第六章代谢性疾病治疗市场：给药途径业务分析

  • 2024 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 2018-2030 年按管理方式分類的市场规模、预测与趋势分析
  • 口服
  • 胃肠外的
  • 其他的

第七章代谢性疾病治疗市场：通路业务分析

  • 2024 年及 2030 年分销通路市场占有率
  • 分销通路细分仪表板
  • 2018-2030 年按分销管道分類的市场规模、预测与趋势分析
  • 医院药房
  • 零售药房
  • 网路药房

第八章代谢紊乱治疗市场：按疾病、治疗方法、给药途径和分销管道分類的地区估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Takeda Pharmaceutical Company Limited
    • Sanofi
    • Merck KGaA
    • AstraZeneca
    • AbbVie Inc.
    • Johnson & Johnson Innovative Medicine
    • Amgen Inc.
    • Biocon
    • BioMarin
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cipla Inc.
Product Code: GVR-3-68038-011-8

Metabolic Disorder Therapeutics Market Growth & Trends:

The global metabolic disorder therapeutics market size is expected to reach USD 120.71 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Metabolic Disorder Therapeutics Market Report Highlights:

  • Diabetes dominated the market and accounted for a share of 29.8% in 2024, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, affecting more than 5% of the global population.
  • Lysosomal storage diseases (LSDs) are expected to grow at the fastest CAGR of 9.3% over the forecast period. LSDs are progressive neurological conditions resulting from enzyme deficiencies, causing severe symptoms and early mortality.
  • Enzyme replacement therapy (ERT) led the market with a revenue share of 30.6% in 2024. ERT targets the fundamental enzyme deficiencies associated with lysosomal storage disorders, significantly improving patient health and quality of life.
  • Gene therapy is anticipated to witness the fastest rate of 9.7% over the forecast period. Gene therapy holds significant potential to offer curative solutions for inherited metabolic diseases with limited treatment options.
  • Parenteral therapeutics held the largest market share of 50.0% in 2024, aided by rapid onset of action and high bioavailability. Parenteral administration effectively bypasses the gastrointestinal tract, avoiding first-pass metabolism, crucial for immediate therapeutic effects.
  • Oral therapeutics are expected to register the fastest CAGR of 8.2% over the forecast period. Oral administration is non-invasive, easy for patients to self-administer, and typically preferred over injections, resulting in higher treatment adherence.
  • Hospital pharmacies dominated the market with a revenue share of 44.6% in 2024. Hospital pharmacies play a vital role in dispensing complex medications, particularly for metabolic disorders that necessitate specialized handling.
  • North America metabolic disorder therapeutics market dominated the global market with a revenue share of 39.9% in 2024. North America boasts a strong healthcare infrastructure, substantial investments in research and development, and a notable prevalence of metabolic disorders such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Therapy
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Metabolic Disorder Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Metabolic Disorder Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 4.4. Lysosomal Storage Diseases
    • 4.4.1. Lysosomal Storage Diseases Market, 2018 - 2030 (USD Million)
  • 4.5. Diabetes
    • 4.5.1. Diabetes Market, 2018 - 2030 (USD Million)
  • 4.6. Obesity
    • 4.6.1. Obesity Market, 2018 - 2030 (USD Million)
  • 4.7. Inherited Metabolic Disorders
    • 4.7.1. Inherited Metabolic Disorders Market, 2018 - 2030 (USD Million)
  • 4.8. Hypercholesterolemia
    • 4.8.1. Hypercholesterolemia Market, 2018 - 2030 (USD Million)
  • 4.9. Other Metabolic Diseases
    • 4.9.1. Other Metabolic Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Metabolic Disorder Therapeutics Market: Therapy Business Analysis

  • 5.1. Therapy Market Share, 2024 & 2030
  • 5.2. Therapy Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Enzyme Replacement Therapy
    • 5.4.1. Enzyme Replacement Therapy Market, 2018 - 2030 (USD Million)
  • 5.5. Cellular Transplantation
    • 5.5.1. Cellular Transplantation Market, 2018 - 2030 (USD Million)
  • 5.6. Small Molecule Based Therapy
    • 5.6.1. Small Molecule Based Therapy Market, 2018 - 2030 (USD Million)
  • 5.7. Substrate Reduction Therapy
    • 5.7.1. Substrate Reduction Therapy Market, 2018 - 2030 (USD Million)
  • 5.8. Gene Therapy
    • 5.8.1. Gene Therapy Market, 2018 - 2030 (USD Million)
  • 5.9. Drug Therapy
    • 5.9.1. Drug Therapy Market, 2018 - 2030 (USD Million)

Chapter 6. Metabolic Disorder Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Parenteral
    • 6.5.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Metabolic Disorder Therapeutics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Metabolic Disorder Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Therapy, Route of Administration, and Distribution Channel

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novo Nordisk A/S
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly and Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Takeda Pharmaceutical Company Limited
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sanofi
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck KGaA
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AbbVie Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Johnson & Johnson Innovative Medicine
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Amgen Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Biocon
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. BioMarin
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Boehringer Ingelheim International GmbH
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Bristol-Myers Squibb Company
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. Cipla Inc.
      • 9.5.14.1. Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global metabolic disorder therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 6. Global metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7. Global metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 10. North America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 11. North America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12. North America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 14. U.S. metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 15. U.S. metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16. U.S. metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Canada metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 19. Canada metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Canada metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Mexico metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 23. Mexico metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Mexico metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 27. Europe metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 28. Europe metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29. Europe metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 31. UK metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 32. UK metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33. UK metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 35. Germany metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 36. Germany metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Germany metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 39. France metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 40. France metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. France metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Italy metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 44. Italy metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. Italy metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 47. Spain metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 48. Spain metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Spain metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Denmark metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 51. Denmark metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 52. Denmark metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53. Denmark metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Sweden metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 55. Sweden metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 56. Sweden metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57. Sweden metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Norway metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 59. Norway metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 60. Norway metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Norway metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. China metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 68. China metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 69. China metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70. China metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. Japan metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Japan metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 73. Japan metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74. Japan metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 76. India metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 77. India metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78. India metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 80. Australia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 81. Australia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82. Australia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 84. South Korea metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 85. South Korea metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86. South Korea metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Thailand metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 89. Thailand metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90. Thailand metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 93. Latin America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 94. Latin America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95. Latin America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 97. Brazil metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 98. Brazil metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99. Brazil metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 101. Argentina metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 102. Argentina metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103. Argentina metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 110. South Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 111. South Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112. South Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 118. UAE metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 119. UAE metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120. UAE metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 122. Kuwait metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 123. Kuwait metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124. Kuwait metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Metabolic disorder therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Disease and therapy outlook (USD Million)
  • Fig. 10 Route of administration and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Metabolic disorder therapeutics market dynamics
  • Fig. 13 Metabolic disorder therapeutics market: Porter's five forces analysis
  • Fig. 14 Metabolic disorder therapeutics market: PESTLE analysis
  • Fig. 15 Metabolic disorder therapeutics market: Disease segment dashboard
  • Fig. 16 Metabolic disorder therapeutics market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Lysosomal storage diseases market, 2018 - 2030 (USD Million)
  • Fig. 18 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 19 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 20 Inherited metabolic disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Hypercholesterolemia market, 2018 - 2030 (USD Million)
  • Fig. 22 Other metabolic diseases market, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolic disorder therapeutics market: Therapy segment dashboard
  • Fig. 24 Metabolic disorder therapeutics market: Therapy market share analysis, 2024 & 2030
  • Fig. 25 Enzyme replacement therapy market, 2018 - 2030 (USD Million)
  • Fig. 26 Cellular transplantation market, 2018 - 2030 (USD Million)
  • Fig. 27 Small molecule based therapy market, 2018 - 2030 (USD Million)
  • Fig. 28 Substrate reduction therapy market, 2018 - 2030 (USD Million)
  • Fig. 29 Gene therapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Drug therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 Metabolic disorder therapeutics market: Route of administration segment dashboard
  • Fig. 32 Metabolic disorder therapeutics market: Route of administration market share analysis, 2024 & 2030
  • Fig. 33 Oral market, 2018 - 2030 (USD Million)
  • Fig. 34 Parenteral market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 Metabolic disorder therapeutics market: Distribution channel segment dashboard
  • Fig. 37 Metabolic disorder therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 39 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 40 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 41 Metabolic disorder therapeutics market revenue, by region
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. country dynamics
  • Fig. 46 U.S. metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Canada country dynamics
  • Fig. 48 Canada metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico country dynamics
  • Fig. 50 Mexico metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 UK country dynamics
  • Fig. 53 UK metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Germany country dynamics
  • Fig. 55 Germany metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 France country dynamics
  • Fig. 57 France metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Italy country dynamics
  • Fig. 59 Italy metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Spain country dynamics
  • Fig. 61 Spain metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 Norway country dynamics
  • Fig. 63 Norway metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Sweden country dynamics
  • Fig. 65 Sweden metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Japan country dynamics
  • Fig. 70 Japan metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 China country dynamics
  • Fig. 72 China metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 India country dynamics
  • Fig. 74 India metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 Australia country dynamics
  • Fig. 76 Australia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea country dynamics
  • Fig. 78 South Korea metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 79 Thailand country dynamics
  • Fig. 80 Thailand metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil country dynamics
  • Fig. 83 Brazil metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina country dynamics
  • Fig. 85 Argentina metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 MEA metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 87 South Africa country dynamics
  • Fig. 88 South Africa metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 89 Saudi Arabia country dynamics
  • Fig. 90 Saudi Arabia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 91 UAE country dynamics
  • Fig. 92 UAE metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait country dynamics
  • Fig. 94 Kuwait metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 95 Company categorization
  • Fig. 96 Company market position analysis
  • Fig. 97 Strategic framework